Quince Stock Price, News & Analysis

Quince Therapeutics (Nasdaq: QNCX) has appointed Dr. Hassan Abolhassani to its Scientific Advisory Board (SAB) as its ninth member. Dr. Abolhassani, an Assistant Professor at the Karolinska Institutet, is a leading immunologist recognized in the top 1% of highly cited researchers in immunology.

The appointment strengthens Quince's SAB as the company advances its lead asset eDSP, currently in a Phase 3 clinical trial for Ataxia-Telangiectasia (A-T). The company expects to report topline results in Q1 2026. Beyond A-T and Duchenne muscular dystrophy, Quince is exploring 11 additional rare disease indications for eDSP where corticosteroid treatment could be beneficial without associated toxicities.

Quince Therapeutics (Nasdaq: QNCX) announced its participation in the 2025 A-T Clinical Research Conference from June 25-27, 2025, at Loughborough University, UK. Key opinion leaders will present post hoc analyses from the Phase 3 ATTeST trial of eDSP, their lead asset for Ataxia-Telangiectasia (A-T) treatment.

The company reported 99 total participants enrolled in their pivotal Phase 3 NEAT clinical trial, including 78 participants aged 6-9 years and 21 participants aged 10 or older. All 42 NEAT participants have opted for the open-label extension study. The company expects to report topline results in Q1 2026 with potential NDA submission in H2 2026.

Notable findings include no serious metabolic or endocrine events in 68 A-T patients treated with eDSP for two years or longer, and the presence of miniATM genes in 40% of patients, correlating with disease severity at baseline.

Quince Therapeutics (QNCX) has closed a private placement of securities worth up to $22 million, priced at a premium. The financing includes $11.5 million in upfront proceeds and potential additional proceeds of $10.4 million from warrant exercises. Led by Nantahala Capital, with participation from ADAR1 Capital Management and company management, the funding extends cash runway through Q2 2026. The company's Phase 3 NEAT trial for Ataxia-Telangiectasia (A-T) has enrolled 95 participants, with topline results expected in Q1 2026. The trial evaluates eDSP, their lead asset which delivers corticosteroid efficacy without toxicity. The FDA has granted Fast Track designation for eDSP in A-T treatment. Funds will support trial completion, pipeline expansion into Duchenne muscular dystrophy, and other rare disease indications.

Quince Therapeutics (QNCX) has secured a private placement of securities expected to generate $11.5 million in upfront proceeds, with potential additional proceeds of up to $10.4 million through warrant exercises. The financing, led by Nantahala Capital with participation from ADAR1 Capital Management and company management, is priced at $1.325 per share, a 10% premium over the previous closing price. The company will issue 8,671,928 shares of common stock with accompanying warrants exercisable at $1.20 per share. The proceeds will fund the ongoing Phase 3 NEAT clinical trial in Ataxia-Telangiectasia, along with general corporate expenses. Combined with existing funds, this financing is expected to extend Quince's operations into Q2 2026, or H2 2026 if warrants are fully exercised.

Quince Therapeutics (QNCX) has achieved over 75% enrollment in its pivotal Phase 3 NEAT clinical trial for Ataxia-Telangiectasia (A-T), a rare neurodegenerative disease. The trial has enrolled 76 participants total, with 65 in the primary analysis group (ages 6-9) out of a target of 86 participants. The study shows strong progress with an 80% power rate and low 10% screen failure rate among 108 screened participants. All 37 eligible participants have opted for the open-label extension study. The trial evaluates eDSP, which has received FDA Fast Track designation, through a randomized, double-blind, placebo-controlled study with six infusions over 21-30 days. Pending positive results, Quince plans to submit an NDA to the FDA in H2 2026.

<p>Quince Therapeutics (Nasdaq: <b>QNCX</b>) announced plans to potentially conclude enrollment early for its Phase 3 NEAT clinical trial in Ataxia-Telangiectasia (A-T) by June 2025. The decision is driven by cash runway considerations and slower than anticipated enrollment. To date, <b>63 participants</b> have been enrolled, including 56 in the primary analysis population. The company reports <b>$31.6 million</b> in cash and investments as of Q1 2025, with a net loss of <b>$15.0 million</b>. Early enrollment conclusion would provide approximately 80% power to determine statistical significance in the primary endpoint, with topline results expected by early 2026. Assuming positive results, Quince plans to submit regulatory applications in the U.S. and Europe in H2 2026.</p>

Quince Therapeutics (Nasdaq: QNCX), a late-stage biotech company focusing on rare disease treatments through patient biology, has announced its upcoming participation in the Citizens Life Sciences Conference.

The company's leadership, represented by Dr. Dirk Thye, who serves as both CEO and Chief Medical Officer, will deliver a presentation at the conference in New York City on May 7, 2025, at 3:30 p.m. Eastern Time.

Investors and interested parties can access the presentation through a live webcast available on the Events page of Quince's Investor Relations website at ir.quincetx.com. A recording of the presentation will be made available shortly after the live event concludes.

Quince Therapeutics (Nasdaq: QNCX), a late-stage biotechnology company focusing on rare disease treatments through patient biology, has announced its upcoming participation in the Jones Healthcare and Technology Innovation Conference.

The company's CEO and CMO, Dr. Dirk Thye, will deliver a presentation on Wednesday, April 9, 2025. Investors and interested parties can access a replay of the presentation through the Events section of Quince's Investor Relations website at ir.quincetx.com.

Quince Therapeutics (NASDAQ: QNCX) reported key progress in its Phase 3 NEAT clinical trial, which has exceeded 50% enrollment with 61 participants randomized. The trial evaluates eDSP for treating Ataxia-Telangiectasia (A-T), with topline results expected in Q4 2025.

The company reported financial results for FY2024:

• Cash position: $40.8 million, expected to fund operations through Phase 3 results into 2026
• R&D expenses: $18.6 million
• G&A expenses: $17.6 million
• Net loss: $56.8 million ($1.31 per share)

Notable developments include FDA Fast Track designation for eDSP, publication of trial results in The Lancet Neurology, and a U.S. patent extension to 2036. The company plans to initiate a Phase 2 trial for Duchenne muscular dystrophy in 2025.